Clinical analysis of low-dos erituximab in the treatment of refractory idiopathic membranous nephropathy
Objective To explore the efficacy and safety of low-dose rituximab(RTX)for refractory idiopathic membranous nephropathy(IMN).Methods From January 2017 to December 2018,32 cases of refractory IMN with positive anti-PLA2 R antibody were collected.They received low-dose RTX treatment and were followed...
Saved in:
| Main Authors: | Yuan Zhong-fei, Liu Xian-yan, He Jian |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2021-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57905525&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of ripertamab in the treatment of idiopathic membranous nephropathy: a retrospective multicenter cohort study
by: Xinyang Li, et al.
Published: (2025-07-01) -
Serumanti-PLA2R antibody predicted treatment outcome in idiopathic membranous nephropathy
by: Zhang Xue-qin, et al.
Published: (2021-01-01) -
Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy
by: Kaiqi Guo, et al.
Published: (2025-07-01) -
Clinical efficacy of tacrolimus combined with glucocorticoids for idiopathic membranous nephropathy
by: LING Yi-sheng, et al.
Published: (2016-01-01) -
How to Choose Treatment Regimens for Idiopathic Membranous Nephropathy Patients with PLA2R-Negative: A Single-Center Retrospective Cohort Study
by: Zhou Z, et al.
Published: (2025-05-01)